UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 131

Sortiert nach

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

Nature biotechnology, 2012-07, Vol.30 (7), p.631

2012

Volltextzugriff (PDF)

Antibody-Drug Conjugates in Cancer Therapy

Annual review of medicine, 2013-01, Vol.64 (1), p.15-29

2013

Volltextzugriff (PDF)

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

Journal of clinical oncology, 2012-06, Vol.30 (18), p.2190-2196

2012

Volltextzugriff (PDF)

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Journal of clinical oncology, 2012-06, Vol.30 (18), p.2183-2189

2012

Volltextzugriff (PDF)

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Blood, 2015-02, Vol.125 (8), p.1236-1243

2015

Volltextzugriff (PDF)

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

Clinical cancer research, 2010-02, Vol.16 (3), p.888-897

2010

Volltextzugriff (PDF)

Incentivized self-vaccination for global measles eradication

Journal of Virus Eradication, 2022-12, Vol.8 (4), p.100310-100310, Article 100310

2022

Volltextzugriff (PDF)

A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

British journal of haematology, 2009-07, Vol.146 (2), p.171-179

2009

Volltextzugriff (PDF)

Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia

Haematologica (Roma), 2013-01, Vol.98 (1), p.119-128

2013

Volltextzugriff (PDF)

Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma

Journal of clinical oncology, 2008-04, Vol.26 (12), p.2034-2039

2008

Volltextzugriff (PDF)

A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders

Clinical cancer research, 2009-10, Vol.15 (19), p.6217-6224

2009

Volltextzugriff (PDF)

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

The New England journal of medicine, 2010-11, Vol.363 (19), p.1812-1821

2010

Volltextzugriff (PDF)

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

Blood, 2002-04, Vol.99 (7), p.2310-2314

2002

Volltextzugriff (PDF)

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Clinical cancer research, 2021-04, Vol.27 (8), p.2190-2199

2021

Volltextzugriff (PDF)

Safety and Efficacy of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group

Journal of clinical oncology, 2008-05, Vol.26 (14), p.2390-2395

2008

Volltextzugriff (PDF)

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

Clinical cancer research, 2017-02, Vol.23 (4), p.1068-1079

2017

Volltextzugriff (PDF)

Inundative, Dry-Powder, Inhaled Measles Vaccination to Prevent Deaths of Young Children in War-torn Regions

Open forum infectious diseases, 2023-06, Vol.10 (6), p.ofad302-ofad302

2023

Volltextzugriff (PDF)

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

Blood, 2001-08, Vol.98 (4), p.988-994

2001

Volltextzugriff (PDF)

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

Clinical cancer research, 2012, Vol.18 (1), p.248-255

2012

Volltextzugriff (PDF)

The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides

Cancer Immunology, Immunotherapy, 2022-04, Vol.71 (4), p.919-932

2022

Volltextzugriff (PDF)

Targeting CD47 in Sézary syndrome with SIRPαFc

Blood advances, 2019-04, Vol.3 (7), p.1145-1153

2019

Volltextzugriff (PDF)

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence

Cancer, 2005-10, Vol.104 (7), p.1442-1452

2005

Volltextzugriff (PDF)

Anti-leukemic activity of Lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia

mAbs, 2009-09, Vol.1 (5), p.481-490

2009

Volltextzugriff (PDF)

5-Azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia

mAbs, 2010-07, Vol.2 (4), p.440-448

2010

Volltextzugriff (PDF)

1 – 25 von 131

Suche als RSS-Feed

Aktive Filter

PublikationsformBücher

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(119)
Mit Volltextzugriff
(122)

Publikationsform

Sprache

Englisch
(131)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Science & Technology
(87)
Life Sciences & Biomedicine
(78)
Humans
(70)
Biological And Medical Sciences
(38)
Medical Sciences
(38)
Male
(35)
Female
(32)
Hematology
(25)
Oncology
(25)
Adult
(22)
Middle Aged
(21)
Hematologic And Hematopoietic Diseases
(18)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(18)
Adolescent
(17)
Aged
(17)
Recurrence
(17)
Child
(16)
Treatment Outcome
(16)
Acute Disease
(15)
Antineoplastic Agents - Therapeutic Use
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

Antibody-Drug Conjugates in Cancer Therapy

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

Incentivized self-vaccination for global measles eradication

A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia

Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma

A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Safety and Efficacy of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

Inundative, Dry-Powder, Inhaled Measles Vaccination to Prevent Deaths of Young Children in War-torn Regions

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides

Targeting CD47 in Sézary syndrome with SIRPαFc

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence

Anti-leukemic activity of Lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia

5-Azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia

Aktive Filter

Suchergebnisse filtern